Study on App-Based Incentives for Older Adults with Substance Use Disorders
This study is crucial as it explores the effectiveness of app-based incentives for older adults, a demographic often overlooked in addiction treatment. The findings could reshape product development and marketing strategies for pharma companies targeting substance use disorders, particularly in the digital therapeutic space.
Phase III
Addiction / Substance Use Disorders
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
This study is crucial as it explores the effectiveness of app-based incentives for older adults, a demographic often overlooked in addiction treatment. The findings could reshape product development and marketing strategies for pharma companies targeting substance use disorders, particularly in the digital therapeutic space.
Why it matters
This study is crucial as it explores the effectiveness of app-based incentives for older adults, a demographic often overlooked in addiction treatment. The findings could reshape product development and marketing strategies for pharma companies targeting substance use disorders, particularly in the digital therapeutic space.
What changed
Trial Update
Analysis
A study is assessing the effectiveness of app-based incentives for older adults with substance use disorders, comparing their engagement and efficacy to younger adults.
This study is crucial as it explores the effectiveness of app-based incentives for older adults, a demographic often overlooked in addiction treatment. The findings could reshape product development and marketing strategies for pharma companies targeting substance use disorders, particularly in the digital therapeutic space.
Monitor results from this study to evaluate the effectiveness of app-based incentives in older adults and any subsequent adaptations in treatment approaches.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.